[go: up one dir, main page]

CL2004001347A1 - Compuestos derivados de 4-[(imidazol-4il)etinil]-piridina sustituidos; procedimientos de preparacion; composicion farmaceutica; y su uso en la elaboracion de un medicamento util para el tratamiento o prevencion de trastornos inducidos por el receptor - Google Patents

Compuestos derivados de 4-[(imidazol-4il)etinil]-piridina sustituidos; procedimientos de preparacion; composicion farmaceutica; y su uso en la elaboracion de un medicamento util para el tratamiento o prevencion de trastornos inducidos por el receptor

Info

Publication number
CL2004001347A1
CL2004001347A1 CL200401347A CL2004001347A CL2004001347A1 CL 2004001347 A1 CL2004001347 A1 CL 2004001347A1 CL 200401347 A CL200401347 A CL 200401347A CL 2004001347 A CL2004001347 A CL 2004001347A CL 2004001347 A1 CL2004001347 A1 CL 2004001347A1
Authority
CL
Chile
Prior art keywords
preparation
ethylin
piridine
imidazol
prevention
Prior art date
Application number
CL200401347A
Other languages
English (en)
Inventor
Buettelmann Simona Maria Bernd
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2004001347A1 publication Critical patent/CL2004001347A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200401347A 2003-06-05 2004-06-02 Compuestos derivados de 4-[(imidazol-4il)etinil]-piridina sustituidos; procedimientos de preparacion; composicion farmaceutica; y su uso en la elaboracion de un medicamento util para el tratamiento o prevencion de trastornos inducidos por el receptor CL2004001347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03012200 2003-06-05

Publications (1)

Publication Number Publication Date
CL2004001347A1 true CL2004001347A1 (es) 2005-05-06

Family

ID=33483899

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401347A CL2004001347A1 (es) 2003-06-05 2004-06-02 Compuestos derivados de 4-[(imidazol-4il)etinil]-piridina sustituidos; procedimientos de preparacion; composicion farmaceutica; y su uso en la elaboracion de un medicamento util para el tratamiento o prevencion de trastornos inducidos por el receptor

Country Status (38)

Country Link
US (3) US7332510B2 (es)
EP (1) EP1636206B1 (es)
JP (1) JP4401384B2 (es)
KR (1) KR100778948B1 (es)
CN (1) CN100408572C (es)
AR (1) AR044478A1 (es)
AT (1) ATE377008T1 (es)
AU (1) AU2004245208B2 (es)
BR (1) BRPI0411095B8 (es)
CA (1) CA2527315C (es)
CL (1) CL2004001347A1 (es)
CR (1) CR8094A (es)
CY (1) CY1107856T1 (es)
DE (1) DE602004009796T2 (es)
DK (1) DK1636206T3 (es)
EA (1) EA010577B1 (es)
EC (1) ECSP056202A (es)
ES (1) ES2294504T3 (es)
GT (1) GT200400117A (es)
HN (1) HN2004000208A (es)
HR (1) HRP20070529T3 (es)
IL (1) IL171930A (es)
MA (1) MA27881A1 (es)
MX (1) MXPA05013149A (es)
MY (2) MY137272A (es)
NO (1) NO332143B1 (es)
NZ (1) NZ543637A (es)
PA (1) PA8604101A1 (es)
PE (1) PE20050162A1 (es)
PL (1) PL1636206T3 (es)
PT (1) PT1636206E (es)
RS (1) RS53183B (es)
SI (1) SI1636206T1 (es)
TN (2) TNSN05309A1 (es)
TW (1) TWI338007B (es)
UA (1) UA80888C2 (es)
WO (1) WO2004108701A1 (es)
ZA (2) ZA200509807B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
HRP20080363T3 (hr) * 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
CN101568531B (zh) * 2006-12-21 2013-11-13 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
BR112013023813A2 (pt) 2011-03-18 2016-12-13 Novartis Ag combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
EP2909180B1 (en) * 2012-10-18 2016-10-05 F. Hoffmann-La Roche AG Ethynyl derivatives as modulators of mglur5 receptor activity
NZ703537A (en) * 2012-10-18 2018-06-29 Hoffmann La Roche Ethynyl derivatives
BR112018069868A2 (pt) * 2016-03-30 2019-01-29 Sinntaxis AB modulador alostérico negativo do receptor metabotrópico de glutamato 5, usos de um nam, e método de tratamento ou atenuação de dano cerebral maduro
JP2023504177A (ja) * 2019-12-02 2023-02-01 エフ.ホフマン-ラ ロシュ アーゲー アルキニル-(ヘテロアリール)-カルボキサミドhcn1阻害剤
EP4161512A1 (en) 2020-06-05 2023-04-12 Noema Pharma AG Methods of treatment of tuberous sclerosis complex
MX2023001288A (es) 2020-07-30 2023-04-28 Noema Pharma Ag Metodos de tratamiento de la neuralgia del trigemino.
EP4658268A1 (en) 2023-02-02 2025-12-10 Noema Pharma AG Methods of treatment of dravet syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508560A (en) * 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU780009B2 (en) * 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ,インコーポレイテッド 神経栄養活性を有する置換5−アルキニルピリミジン
HUP0400570A3 (en) * 2000-12-04 2004-09-28 Hoffmann La Roche Phenylethenyl or phenylethinyl heteroaril derivatives as glutamate receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
AU2002360621B2 (en) * 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
JP2006513996A (ja) * 2002-10-24 2006-04-27 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives

Also Published As

Publication number Publication date
WO2004108701A1 (en) 2004-12-16
SI1636206T1 (sl) 2008-02-29
PL1636206T3 (pl) 2008-04-30
PT1636206E (pt) 2008-01-28
AU2004245208A1 (en) 2004-12-16
EP1636206B1 (en) 2007-10-31
DE602004009796T2 (de) 2008-08-28
BRPI0411095B8 (pt) 2021-05-25
PE20050162A1 (es) 2005-03-22
MY137272A (en) 2009-01-30
TW200509920A (en) 2005-03-16
HN2004000208A (es) 2009-02-03
CY1107856T1 (el) 2013-06-19
HK1093070A1 (zh) 2007-02-23
BRPI0411095B1 (pt) 2018-04-03
DE602004009796D1 (de) 2007-12-13
ES2294504T3 (es) 2008-04-01
TNSN06391A1 (fr) 2008-02-22
GT200400117A (es) 2005-02-07
IL171930A0 (en) 2006-04-10
CA2527315A1 (en) 2004-12-16
NO332143B1 (no) 2012-07-02
EP1636206A1 (en) 2006-03-22
ZA200609681B (en) 2008-06-25
AU2004245208B2 (en) 2007-04-26
ZA200509807B (en) 2006-12-27
ATE377008T1 (de) 2007-11-15
US20080119489A1 (en) 2008-05-22
HRP20070529T3 (hr) 2008-05-31
CN100408572C (zh) 2008-08-06
MXPA05013149A (es) 2006-03-17
RS20050892A (sr) 2007-12-31
ECSP056202A (es) 2006-04-19
KR100778948B1 (ko) 2007-11-28
EA010577B1 (ru) 2008-10-30
JP2006526588A (ja) 2006-11-24
US7332510B2 (en) 2008-02-19
UA80888C2 (en) 2007-11-12
AR044478A1 (es) 2005-09-14
US20040248888A1 (en) 2004-12-09
US8481548B2 (en) 2013-07-09
TWI338007B (en) 2011-03-01
IL171930A (en) 2010-12-30
DK1636206T3 (da) 2008-02-11
EA200501887A1 (ru) 2006-10-27
JP4401384B2 (ja) 2010-01-20
BRPI0411095A (pt) 2006-07-18
KR20060057537A (ko) 2006-05-26
US20080103306A1 (en) 2008-05-01
NZ543637A (en) 2008-04-30
CR8094A (es) 2006-05-30
NO20055465L (no) 2005-11-18
TNSN05309A1 (fr) 2007-07-10
MA27881A1 (fr) 2006-05-02
RS53183B (sr) 2014-06-30
US7973165B2 (en) 2011-07-05
CN1802367A (zh) 2006-07-12
CA2527315C (en) 2010-08-10
PA8604101A1 (es) 2004-12-16
MY143353A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
CL2004001347A1 (es) Compuestos derivados de 4-[(imidazol-4il)etinil]-piridina sustituidos; procedimientos de preparacion; composicion farmaceutica; y su uso en la elaboracion de un medicamento util para el tratamiento o prevencion de trastornos inducidos por el receptor
CL2004000889A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
CL2007001006A1 (es) Compuestos derivados de piperidina u 8-aza-biciclo[3.2.1]octano sustituidos; formulacion farmaceutica; producto; y uso para el tratamiento o prevencion de enfermedades tales como diabetes mellitus no insulino dependiente, artritis, obesidad, dislipid
IL189499A (en) Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
BRPI0507497A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
BRPI0407097A (pt) Antagonista do casr
IL176519A0 (en) Directly compressible pharmaceutical composition for the oral administration of cci-779
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
WO2007044804A3 (en) Piperidine derivatives and methods of use
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120284A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
CL2007003189A1 (es) Compuestos derivados de indol y benzofurano; composicion farmaceutica; y uso para el tratamiento o la prevencion de la enfermedad de alzheimer.
EP1861358A4 (en) NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME